GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Resonance Health Ltd (STU:RSN) » Definitions » EV-to-EBITDA

Resonance Health (STU:RSN) EV-to-EBITDA : -32.58 (As of May. 27, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Resonance Health EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Resonance Health's enterprise value is €20.24 Mil. Resonance Health's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.62 Mil. Therefore, Resonance Health's EV-to-EBITDA for today is -32.58.

The historical rank and industry rank for Resonance Health's EV-to-EBITDA or its related term are showing as below:

STU:RSN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -668.3   Med: -14.84   Max: 777.95
Current: -23.28

During the past 13 years, the highest EV-to-EBITDA of Resonance Health was 777.95. The lowest was -668.30. And the median was -14.84.

STU:RSN's EV-to-EBITDA is ranked worse than
100% of 465 companies
in the Healthcare Providers & Services industry
Industry Median: 12.65 vs STU:RSN: -23.28

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-27), Resonance Health's stock price is €0.054. Resonance Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €0.000. Therefore, Resonance Health's PE Ratio for today is N/A.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Resonance Health EV-to-EBITDA Historical Data

The historical data trend for Resonance Health's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resonance Health EV-to-EBITDA Chart

Resonance Health Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39.02 -71.17 113.55 -14.38 -11.18

Resonance Health Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -14.38 - -11.18 -

Competitive Comparison of Resonance Health's EV-to-EBITDA

For the Health Information Services subindustry, Resonance Health's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Resonance Health's EV-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Resonance Health's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Resonance Health's EV-to-EBITDA falls into.



Resonance Health EV-to-EBITDA Calculation

Resonance Health's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=20.235/-0.621
=-32.58

Resonance Health's current Enterprise Value is €20.24 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Resonance Health's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.62 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Resonance Health  (STU:RSN) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Resonance Health's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.054/0.000
=N/A

Resonance Health's share price for today is €0.054.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Resonance Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Resonance Health EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Resonance Health's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Resonance Health (STU:RSN) Business Description

Traded in Other Exchanges
Address
141 Burswood Road, Level 1, Burswood, WA, AUS, 6100
Resonance Health Ltd is a healthcare company specializing in the development and commercialization of technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. Its product includes FerriScan, a non-invasive liver diagnostic technology used for the measurement of iron in the liver, and HepaFat-Scan. The company's operating segment includes Services; Research and Development and Corporate. It generates maximum revenue from the Services segment. Geographically, it derives a majority of its revenue from North America and Europe-Middle-East-Africa (EMEA) and also has a presence in Asia/Pacific.

Resonance Health (STU:RSN) Headlines

No Headlines